Meridian Bioscience, Inc. (VIVO)
Jan 31, 2023 - VIVO was delisted (reason: acquired by SD Biosensor and SJL Partners)
33.97
0.00 (0.00%)
Last trade price
Balance Sheet (Annual)
Financials in millions USD. Fiscal year is October - September.
Millions USD. Fiscal year is Oct - Sep.
Year | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 - 1996 |
---|---|---|---|---|---|---|---|---|---|---|---|
Cash & Equivalents
|
81.45 | 49.77 | 53.51 | 62.4 | 60.76 | 58.07 | 48.23 | 50.97 | 44.05 | 45.28 | Upgrade
|
Cash & Cash Equivalents
|
81.45 | 49.77 | 53.51 | 62.4 | 60.76 | 58.07 | 48.23 | 50.97 | 44.05 | 45.28 | Upgrade
|
Cash Growth
|
63.66% | -6.99% | -14.24% | 2.69% | 4.63% | 20.42% | -5.39% | 15.72% | -2.73% | 38.93% | Upgrade
|
Receivables
|
47.24 | 53.57 | 38.51 | 36.7 | 32.34 | 29.11 | 27.1 | 26.25 | 23.23 | 26.18 | Upgrade
|
Inventory
|
67.81 | 76.84 | 61.26 | 39.62 | 41.99 | 41.49 | 45.06 | 35.82 | 35.5 | 34.84 | Upgrade
|
Other Current Assets
|
14.1 | 12.63 | 8.9 | 6.05 | 3.96 | 5.2 | 6.41 | 6.38 | 9.97 | 7.79 | Upgrade
|
Total Current Assets
|
210.6 | 192.81 | 162.19 | 144.76 | 139.05 | 133.88 | 126.79 | 119.42 | 112.75 | 114.09 | Upgrade
|
Property, Plant & Equipment
|
50.71 | 49 | 37.46 | 30.57 | 30 | 30.51 | 30.45 | 27.49 | 27.61 | 26.09 | Upgrade
|
Goodwill and Intangibles
|
190.43 | 198.82 | 197.38 | 149.48 | 77.75 | 81.63 | 91.84 | 28.28 | 31.01 | 31.17 | Upgrade
|
Other Long-Term Assets
|
11.36 | 9.1 | 8.23 | 0.67 | 4.58 | 3.76 | 2.95 | 8.09 | 5.57 | 5.4 | Upgrade
|
Total Long-Term Assets
|
252.5 | 256.92 | 243.07 | 180.72 | 112.32 | 115.9 | 125.24 | 63.86 | 64.18 | 62.66 | Upgrade
|
Total Assets
|
463.1 | 449.72 | 405.26 | 325.48 | 251.38 | 249.78 | 252.03 | 183.28 | 176.93 | 176.75 | Upgrade
|
Accounts Payable
|
17.76 | 11.7 | 11.97 | 7.24 | 6.26 | 7.72 | 7.63 | 6.65 | 4.97 | 5.59 | Upgrade
|
Current Debt
|
2.5 | 2.63 | 2.39 | 0 | 5.25 | 4.5 | 3.75 | 0 | 0 | 0 | Upgrade
|
Other Current Liabilities
|
37.7 | 32.83 | 38.17 | 13.68 | 12.66 | 10.67 | 11.19 | 8.61 | 8.77 | 14.03 | Upgrade
|
Total Current Liabilities
|
57.95 | 47.16 | 52.52 | 20.91 | 24.17 | 22.89 | 22.57 | 15.25 | 13.74 | 19.62 | Upgrade
|
Long-Term Debt
|
33.75 | 69.11 | 84.03 | 75.82 | 44.93 | 50.15 | 54.61 | 0 | 0 | 0 | Upgrade
|
Other Long-Term Liabilities
|
3.34 | 5.16 | 21.08 | 37.77 | 6.86 | 7.16 | 8.38 | 2.16 | 2.17 | 2.09 | Upgrade
|
Total Long-Term Liabilities
|
37.09 | 74.26 | 105.11 | 113.6 | 51.79 | 57.31 | 62.99 | 2.16 | 2.17 | 2.09 | Upgrade
|
Total Liabilities
|
95.04 | 121.42 | 157.63 | 134.51 | 75.96 | 80.19 | 85.56 | 17.41 | 15.9 | 21.7 | Upgrade
|
Total Debt
|
36.24 | 71.74 | 86.42 | 75.82 | 50.18 | 54.65 | 58.36 | 0 | 0 | 0 | Upgrade
|
Debt Growth
|
-49.48% | -16.99% | 13.97% | 51.10% | -8.17% | -6.36% | - | - | - | - | Upgrade
|
Common Stock
|
155.41 | 147.4 | 140.2 | 132.83 | 129.19 | 125.61 | 122.36 | 117.15 | 111.85 | 107.41 | Upgrade
|
Retained Earnings
|
223.16 | 180.7 | 109.29 | 63.11 | 49.6 | 46.92 | 49.63 | 51.05 | 48.87 | 46.89 | Upgrade
|
Comprehensive Income
|
-10.5 | 0.2 | -1.86 | -4.98 | -3.38 | -2.95 | -5.52 | -2.33 | 0.31 | 0.75 | Upgrade
|
Shareholders' Equity
|
368.06 | 328.3 | 247.63 | 190.97 | 175.42 | 169.59 | 166.47 | 165.87 | 161.03 | 155.05 | Upgrade
|
Total Liabilities and Equity
|
463.1 | 449.72 | 405.26 | 325.48 | 251.38 | 249.78 | 252.03 | 183.28 | 176.93 | 176.75 | Upgrade
|
Net Cash / Debt
|
45.21 | -21.97 | -32.9 | -13.43 | 10.58 | 3.43 | -10.13 | 50.97 | 44.05 | 45.28 | Upgrade
|
Net Cash / Debt Growth
|
- | - | - | - | 208.99% | - | - | 15.72% | -2.73% | 38.93% | Upgrade
|
Net Cash Per Share
|
1.02 | -0.50 | -0.76 | -0.31 | 0.25 | 0.08 | -0.24 | 1.21 | 1.05 | 1.08 | Upgrade
|
Working Capital
|
152.65 | 145.65 | 109.67 | 123.85 | 114.88 | 110.99 | 104.22 | 104.17 | 99.01 | 94.47 | Upgrade
|
Book Value Per Share
|
8.45 | 7.59 | 5.78 | 4.49 | 4.14 | 4.02 | 3.96 | 3.98 | 3.88 | 3.76 | Upgrade
|
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).